RxDoctor Payments Data

Manolito Cadacio, MD

Internal Medicine · Somers Point, NJNPI 1447440680

Payments from drug & device makers

$2,716in general payments, 2019–2025

Across 153 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$497
  • Amgen$387
  • AstraZeneca$305
  • AbbVie$251
  • Lilly USA, LLC$246
  • Pfizer$239
  • plus $790 from 16 others

What the payments were for

  • Food & beverage$2,716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,716 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$132,872
Medicare patients
306
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$105,515
EliquisApixaban46$69,111
JanuviaSitagliptin Phosphate41$50,796
OzempicSemaglutide33$47,331
FarxigaDapagliflozin Propanediol37$40,532
InvokanaCanagliflozin17$27,443
Rosuvastatin Calcium324$6,588
Atorvastatin Calcium467$5,706
Valsartan130$5,112
SynthroidLevothyroxine Sodium51$4,439
Incruse ElliptaUmeclidinium Bromide12$4,415
Levothyroxine Sodium297$3,136
Losartan Potassium240$2,495
Clozapine13$2,400
Omeprazole207$2,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$239$69,11146 claims
MerckJanuvia$29$50,79641 claims
Novo NordiskOzempic$497$47,33133 claims
AstraZenecaFarxiga$305$40,53237 claims
Johnson & JohnsonInvokana$74$27,44317 claims
AbbVieSynthroid$251$4,43951 claims
GSKIncruse Ellipta$31$4,41512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →